Scientech Research LLC Increases Stock Position in Axon Enterprise, Inc. (NASDAQ:AXON)

Scientech Research LLC raised its holdings in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 152.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,006 shares of the biotechnology company's stock after purchasing an additional 1,212 shares during the period. Scientech Research LLC's holdings in Axon Enterprise were worth $1,192,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Siemens Fonds Invest GmbH raised its position in shares of Axon Enterprise by 219.7% in the fourth quarter. Siemens Fonds Invest GmbH now owns 2,481 shares of the biotechnology company's stock valued at $1,475,000 after buying an additional 1,705 shares in the last quarter. Skye Global Management LP acquired a new position in Axon Enterprise during the fourth quarter valued at approximately $1,902,000. Shell Asset Management Co. raised its position in Axon Enterprise by 7.5% during the fourth quarter. Shell Asset Management Co. now owns 2,449 shares of the biotechnology company's stock valued at $1,455,000 after purchasing an additional 170 shares in the last quarter. Rafferty Asset Management LLC raised its position in Axon Enterprise by 74.7% during the fourth quarter. Rafferty Asset Management LLC now owns 36,839 shares of the biotechnology company's stock valued at $21,894,000 after purchasing an additional 15,747 shares in the last quarter. Finally, Raiffeisen Bank International AG acquired a new position in Axon Enterprise during the fourth quarter valued at approximately $1,917,000. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Axon Enterprise Stock Up 0.1%

Shares of AXON traded up $0.43 on Tuesday, hitting $742.75. 383,468 shares of the stock traded hands, compared to its average volume of 751,632. The company has a market capitalization of $57.82 billion, a PE ratio of 191.93, a P/E/G ratio of 5.17 and a beta of 1.24. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. The business has a 50 day simple moving average of $592.46 and a 200 day simple moving average of $598.92. Axon Enterprise, Inc. has a one year low of $273.52 and a one year high of $744.51.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.07. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. The company had revenue of $603.63 million for the quarter, compared to analysts' expectations of $585.67 million. During the same quarter last year, the company posted $1.15 earnings per share. The firm's quarterly revenue was up 31.3% on a year-over-year basis. As a group, equities analysts forecast that Axon Enterprise, Inc. will post 5.8 earnings per share for the current fiscal year.

Insider Transactions at Axon Enterprise

In other news, Director Jeri Williams sold 307 shares of Axon Enterprise stock in a transaction on Monday, March 17th. The shares were sold at an average price of $552.72, for a total transaction of $169,685.04. Following the transaction, the director now owns 1,627 shares in the company, valued at $899,275.44. This trade represents a 15.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Matthew R. Mcbrady sold 400 shares of Axon Enterprise stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $718.40, for a total transaction of $287,360.00. Following the transaction, the director now owns 3,492 shares in the company, valued at approximately $2,508,652.80. This trade represents a 10.28% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 25,064 shares of company stock worth $15,817,127 in the last 90 days. 4.40% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

AXON has been the subject of several research analyst reports. JMP Securities restated an "outperform" rating on shares of Axon Enterprise in a research report on Tuesday, February 4th. Barclays upped their price target on shares of Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. Northcoast Research downgraded shares of Axon Enterprise from a "buy" rating to a "neutral" rating in a report on Wednesday, February 19th. Craig Hallum downgraded shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a report on Monday, March 10th. Finally, Needham & Company LLC upped their price target on shares of Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $652.73.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.